1 World Health Organization. WHO coronavirus disease (covid-19) dashboard, <https://covid19.who.int/> (2021, May 17).
2 Guo, T. et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 5, 811-818, doi:10.1001/jamacardio.2020.1017 (2020).
3 Shi, S. et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 5, 802-810, doi:10.1001/jamacardio.2020.0950 (2020).
4 Lala, A. et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol 76, 533-546, doi:10.1016/j.jacc.2020.06.007 (2020).
5 Lombardi, C. M. et al. Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study. JAMA Cardiol 5, 1274-1280, doi:10.1001/jamacardio.2020.3538 (2020).
6 Smilowitz, N. R. et al. Myocardial Injury in Adults Hospitalized With COVID-19. Circulation 142, 2393-2395, doi:10.1161/CIRCULATIONAHA.120.050434 (2020).
7 Bilaloglu, S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 324, 799-801, doi:10.1001/jama.2020.13372 (2020).
8 Rey, J. R. et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail, doi:10.1002/ejhf.1990 (2020).
9 Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417-1418, doi:10.1016/S0140-6736(20)30937-5 (2020).
10 Fox, S. E. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8, 681-686, doi:10.1016/S2213-2600(20)30243-5 (2020).
11 Basso, C. et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 41, 3827-3835, doi:10.1093/eurheartj/ehaa664 (2020).
12 Halushka, M. K. & Vander Heide, R. S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol 50, 107300, doi:10.1016/j.carpath.2020.107300 (2020).
13 Pellegrini, D. et al. Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. Circulation 143, 1031-1042, doi:10.1161/CIRCULATIONAHA.120.051828 (2021).
14 Sandoval, Y., Januzzi, J. L., Jr. & Jaffe, A. S. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 76, 1244-1258, doi:10.1016/j.jacc.2020.06.068 (2020).
15 Giustino, G. et al. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol 76, 2043-2055, doi:10.1016/j.jacc.2020.08.069 (2020).
16 Basisty, N. et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol 18, e3000599, doi:10.1371/journal.pbio.3000599 (2020).
17 Leppkes, M. et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 58, 102925, doi:10.1016/j.ebiom.2020.102925 (2020).
18 Cash, H. L., Whitham, C. V., Behrendt, C. L. & Hooper, L. V. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313, 1126-1130, doi:10.1126/science.1127119 (2006).
19 Choi, S. M. et al. Innate Stat3-mediated induction of the antimicrobial protein Reg3gamma is required for host defense against MRSA pneumonia. J Exp Med 210, 551-561, doi:10.1084/jem.20120260 (2013).
20 Cremer, H. et al. Inactivation of the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning. Nature 367, 455-459, doi:10.1038/367455a0 (1994).
21 Levy, G. G. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413, 488-494, doi:10.1038/35097008 (2001).
22 Tostanoski, L. H. et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med 26, 1694-1700, doi:10.1038/s41591-020-1070-6 (2020).
23 Dweck, M. R. et al. Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imaging 21, 949-958, doi:10.1093/ehjci/jeaa178 (2020).
24 Giustino, G. et al. Takotsubo Cardiomyopathy in COVID-19. J Am Coll Cardiol 76, 628-629, doi:10.1016/j.jacc.2020.05.068 (2020).
25 Roh, J. D. et al. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med 11, doi:10.1126/scitranslmed.aau8680 (2019).
26 Koncarevic, A. et al. A novel therapeutic approach to treating obesity through modulation of TGFbeta signaling. Endocrinology 153, 3133-3146, doi:10.1210/en.2012-1016 (2012).
27 Dobaczewski, M., Chen, W. & Frangogiannis, N. G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 51, 600-606, doi:10.1016/j.yjmcc.2010.10.033 (2011).
28 Scully, M. et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood 130, 2055-2063, doi:10.1182/blood-2017-06-788026 (2017).
29 Fenaux, P. et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med 382, 140-151, doi:10.1056/NEJMoa1908892 (2020).
30 Rovas, A. et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis, doi:10.1007/s10456-020-09753-7 (2020).
31 Bazzan, M. et al. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med 15, 861-863, doi:10.1007/s11739-020-02394-0 (2020).
32 Tiscia, G. L. et al. Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients. TH Open 4, e203-e206, doi:10.1055/s-0040-1716379 (2020).
33 Investigators, I. et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA, doi:10.1001/jama.2021.4152 (2021).
34 Turecek, P. L. et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res 201, 100-112, doi:10.1016/j.thromres.2021.02.012 (2021).
35 Fitzgibbons, T. P. et al. Activation of Inflammatory and Pro-Thrombotic Pathways in Acute Stress Cardiomyopathy. Front Cardiovasc Med 4, 49, doi:10.3389/fcvm.2017.00049 (2017).
36 Newton-Cheh, C. et al. Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock. N Engl J Med 383, 475-484, doi:10.1056/NEJMcpc2004975 (2020).
37 Yung, L. M. et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med 12, doi:10.1126/scitranslmed.aaz5660 (2020).
38 Apostolou, E. et al. Activin-A overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. Am J Respir Crit Care Med 185, 382-391, doi:10.1164/rccm.201105-0784OC (2012).
39 Pittet, J. F. et al. TGF-beta is a critical mediator of acute lung injury. J Clin Invest 107, 1537-1544, doi:10.1172/JCI11963 (2001).
40 Travis, M. A. & Sheppard, D. TGF-beta activation and function in immunity. Annu Rev Immunol 32, 51-82, doi:10.1146/annurev-immunol-032713-120257 (2014).
41 Wiley, C. D. et al. SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells. Cell Rep 28, 3329-3337 e3325, doi:10.1016/j.celrep.2019.08.049 (2019).
42 Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. Science 369, 256-257, doi:10.1126/science.abb0762 (2020).
43 Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G. & Demaria, M. Cellular senescence as a potential mediator of COVID-19 severity in the elderly. Aging Cell 19, e13237, doi:10.1111/acel.13237 (2020).
44 Cox, L. S. et al. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. Lancet Healthy Longev 1, e55-e57, doi:10.1016/S2666-7568(20)30011-8 (2020).
45 Thygesen, K. et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 72, 2231-2264, doi:10.1016/j.jacc.2018.08.1038 (2018).
46 Filbin, M. R. et al. Longitudinal proteomic analysis of plasma from patients with severe COVID-19 reveal patient survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med, 100287, doi:10.1016/j.xcrm.2021.100287 (2021).
47 Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, doi:10.7554/eLife.34408 (2018).
48 Aid, M. et al. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell 183, 1354-1366 e1313, doi:10.1016/j.cell.2020.10.005 (2020).